Side-by-Side Comparison
CJC-1295 vs Sermorelin: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how CJC-1295 and Sermorelin differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
CJC-1295
L3Also: CJC-1295 DAC, CJC-1295 without DAC, Modified GRF 1-29
A growth hormone-releasing hormone (GHRH) analog studied for its ability to increase growth hormone and IGF-1 levels.
Also: Geref, GHRH(1-29)NH2
A growth hormone-releasing hormone analog with a long history of clinical use for GH deficiency diagnosis and therapy.
Side-by-side comparison
| Attribute | CJC-1295 | Sermorelin |
|---|---|---|
| Primary mechanism | GHRH Receptor Agonism | GHRH Receptor Agonism |
| FDA status | Banned from Compounding (Category 2) | FDA Approved |
| Evidence level | Emerging Clinical Evidence | Strong Clinical Evidence |
| Human trials | Yes (3+ indexed) | Yes (15+ indexed) |
| Studies indexed | 24 total (5 human, 12 animal) | 51 total (22 human, 15 animal) |
| Primary uses researched | Growth hormone release, Body composition, Recovery | Growth hormone stimulation, Anti-aging, Sleep quality, Body composition |
| Administration routes | subcutaneous | subcutaneous |
| Molecular weight | 3367.97 Da | 3357.93 Da |
| Amino acids | 30 | 29 |
| Category | growth hormone | growth hormone |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. Both compounds share the same primary mechanism (ghrh receptor agonism), so differences between them are driven by pharmacokinetics, selectivity, and clinical data rather than mechanism class.
Regulatory status. CJC-1295 is classified as banned from compounding (category 2); Sermorelin is classified as fda approved. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Sermorelin sits at a higher evidence level (L4) than CJC-1295 (L3) under PeptideMark's L1–L5 methodology.
Research focus. Published research on CJC-1295 has concentrated on growth hormone release, body composition, recovery. Research on Sermorelin has concentrated on growth hormone stimulation, anti-aging, sleep quality. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | CJC-1295 | Sermorelin |
|---|---|---|
| Documented effects | 8 total | 6 total |
| Serious events | 0 | 0 |
| Common events | 2 | 1 |
| Black box warning | No | No |
| Contraindications | 4 listed | 3 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
CJC-1295
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Prohibited in competitive sport under WADA
Sermorelin
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L4)
- Multiple human clinical trials (15+ indexed)
Limitations
- Prohibited in competitive sport under WADA
Representative studies
CJC-1295
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, et al. · Journal of Clinical Endocrinology & Metabolism (2006)
CJC-1295 DAC produced dose-dependent, sustained increases in GH and IGF-1 with cumulative effects from repeated dosing — the foundational human pharmacokinetic data.
PubMed 16352683Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Bhatt DL. · Journal of Clinical Endocrinology & Metabolism (2006)
CJC-1295 preserves pulsatile GH secretion during continuous stimulation — the enhanced trough GH levels (not pulse amplitude) drive the IGF-1 increase.
PubMed 17018654Sermorelin
Two years of continuous subcutaneous infusion of GHRH(1-29)NH2 in GH deficient adults
Vittone J, et al. · Pituitary (1997)
Two years of sermorelin treatment maintained increased IGF-1 levels and improved lean body mass in GH-deficient adults.
PubMed 9452117Sermorelin Acetate Treatment in Growth Hormone Deficient Children: 2-Year Randomized Double-Blind Trial
Laron Z, Parks JS, Adler GK, et al. · Journal of Clinical Endocrinology & Metabolism (1995)
Sermorelin increased mean height velocity from 4.2 to 8.1 cm/year and serum IGF-1 by 247% compared to baseline; sustained over 24 months.
PubMed 7852385Frequently asked
What is the main difference between CJC-1295 and Sermorelin?
CJC-1295 is a growth hormone-releasing hormone (ghrh) analog studied for its ability to increase growth hormone and igf-1 levels. Its primary mechanism is ghrh receptor agonism. Sermorelin is a growth hormone-releasing hormone analog with a long history of clinical use for gh deficiency diagnosis and therapy. Its primary mechanism is ghrh receptor agonism. The two differ in regulatory status (Banned from Compounding (Category 2) vs FDA Approved), strength of evidence (L3 vs L4), and the primary conditions for which each is researched.
Is CJC-1295 or Sermorelin FDA approved?
CJC-1295: Placed on FDA Category 2 list. Not approved for human use. Previously available from compounding pharmacies as a growth hormone secretagogue. Sermorelin: Previously FDA-approved as a diagnostic agent for GH deficiency (Geref). The commercial product was discontinued but sermorelin remains available through compounding pharmacies.
How does the evidence base compare?
CJC-1295 has 24 indexed studies (5 human, 12 animal) and is rated Emerging Clinical Evidence. Sermorelin has 51 indexed studies (22 human, 15 animal) and is rated Strong Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can CJC-1295 and Sermorelin be compared directly?
Yes — both compounds share the growth hormone category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are CJC-1295 and Sermorelin commonly stacked together?
There is no widely documented stacking protocol combining CJC-1295 and Sermorelin in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, CJC-1295 or Sermorelin?
CJC-1295 has 8 documented side effects (0 serious). Sermorelin has 6 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are CJC-1295 and Sermorelin administered?
Both are administered via subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, CJC-1295 or Sermorelin?
"Better" depends on the therapeutic goal, regulatory context, and individual response. CJC-1295 is most researched for growth hormone release and body composition; Sermorelin is most researched for growth hormone stimulation and anti-aging. FDA status also matters: Banned from Compounding (Category 2) for CJC-1295 vs FDA Approved for Sermorelin. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
CJC-1295 →
Full profile
Sermorelin →